Antineutrophil cytoplasmic antibody measurement: Advantages and disadvantages of a capture PR3 ELISA and a direct PR3 ELISA

Pathology

Volumn 39, Issue 2, 2007, Pages 258-263

  O'Donnell, John L ^a,b,c   Hayman, Matthew W ^a   Spellerberg, Myfanwy B ^a,b   McLellan, Alexander D ^a   Brooksbank, Katriona ^a   Chapman, Peter T ^a,b   Stamp, Lisa K ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

Capture PR3 ELISA; Direct PR3 ELISA; Measurement; PR3 ANCA

Indexed keywords

MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANALYTIC METHOD; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; INTERMETHOD COMPARISON; LABORATORY TEST; PATIENT MONITORING; SCREENING TEST; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE REACTIONS; HUMANS; MYELOBLASTIN; SENSITIVITY AND SPECIFICITY; WEGENER GRANULOMATOSIS;

EID: 33947312000     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020701230641     Document Type: Article

References (20)

1. Kallenberg CGM, Rarok A, Stegeman CA, Limburg PC. New insights into the pathogenesis of antineutrophil cytoplasmic autoantibodyassociated vasculitis. Autoimmun Rev 2002; 1: 61-6.
2. Heeringa P, Huugen D, Cohen Tervaert JW. Anti-neutrophil autoantibodies and leukocyte-endothelial interaction: a sticky connection? Trends Immunol 2005; 26: 561-4.
3. Baslund B, Segelmark M, Wiik A, Szpirt W, Petersen J, Wieslander J. Screening for anti-neutrophil cytoplasmic antibodies (ANCA): is indirect immunofluorescence the method of choice? Clin Exp Immunol 1995; 99: 486-92.
4. Savige J, Gillis D, Benson E, et al. International Consensus Statement on Testing and Reporting of ANCA. Am J Clin Pathol 1999; 111: 507-13.
5. Trevisin M, Neeson P, Savige J. The binding of proteinase 3 antineutrophil cytoplasmic antibodies (PR3-ANCA) varies in different ELISAs. J Clin Pathol 2004; 57: 303-8.
6. Westman KW, Selga D, Bygren P, Segelmark M, et al. Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody. Kidney Int 1998; 53: 1230-6.
7. Csernok E, Holle J, Hellmich B, et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology 2004; 43: 174-80.
8. International Accreditation New Zealand (IANZ). IANZ Standard NZS/ISO 15189:2003 (Medical Laboratories - Particular requirements for quality and competence). Auckland: IANZ, 2003.
9. Gibson A, Stamp LK, Chapman PT, O'Donnell JL. The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology 2006; 45: 624-8.
10. Witko-Sarsat V, Halbwachs-Mecarelli L, Almeida RP, et al. Characterisation of a recombinant proteinase 3, the autoantigen in Wegener's granulomatosis and its reactivity with anti-neutrophil cytoplasmic autoantibodies. FEBS Lett 1996; 382: 130-6.
11. van Rossum AP, van der Geld YM, Limberg PC, Kallenberg CG. Human anti-neutrophil cytoplasmic autoantibodies to proteinase 3 (PR3-ANCA) bind to neutrophils. Kidney Int 2005; 68: 537-41.
12. Cohen Tervaert JW, van der Woude FJ, Fauci AS, et al. Association between active WG and cytoplasmic antibodies. Arch Intern Med 1989; 149: 2461-5.
13. Jayne DRW, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM 1995; 149: 1-15.
14. Cohen Tervaert JW, Huitema MG, Hené RJ, et al. Prevention of relapses in Wegener's granulomatosis by treatment based and antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-11.
15. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in WG by measurement of ANCA levels. Arthritis Rheum 2000; 43: 2025-33.
16. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titre in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36: 365-71.
17. Esser P. Principles in adsorption to polystyrene. Nunc Laboratories Bulletin 1988; 6: 317-21. http://www.nuncbrand.com/page/en/579.aspx, accessed Oct 2006.
18. Specks U. What you should know about PR3-ANCA conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition of PR3-ANCA. Arthritis Res 2000; 2: 263-7. http:// arthritis-research.com/content/2/4/ 263, accessed Oct 2006.
19. Fujinaga M, Chernaia MM, Halenbeck R, Koths K, James MNG. The crystal structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies. J Mol Biol 1996; 261: 267-78.
20. Gissen K, Wieslander J, Westberg G, Herlitz H. Relationship between anti-neutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long-term clinical course in vasculitis. J Int Med 2002; 251: 129-35.